Homocysteine and methylenetetrahydrofolate reductase polymorphism in Alzheimer's disease

NeuroReport

Volumn 15, Issue 5, 2004, Pages 859-861

  Anello, Guido ^a   Guéant Rodríguez, Rosa Maria ^b   Bosco, Paolo ^a   Guéant, Jean Louis ^b   Romano, Antonino ^c   Namour, Bernard ^b   Spada, Rosario ^a   Caraci, Filippo ^d   Pourié, Gregory ^b   Daval, Jean Luc ^b   Ferri, Raffaele ^a  

^a OASI RESEARCH INSTITUTE IRCCS   (Italy)

^b UNIVERSITÉ DE LORRAINE   (France)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

Author keywords

Alzheimer's disease; Homocysteine; Methylene tetrahydrofolate reductase; Transcobalamin

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADENINE; APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON 4; CYTOSINE; GUANOSINE; HOMOCYSTEINE; THYMINE; TRANSCOBALAMIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; AMINO ACID METABOLISM; ARTICLE; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; ITALY; MAJOR CLINICAL STUDY; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL;

AGE FACTORS; AGED; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; FEMALE; HOMOCYSTEINE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; POLYMORPHISM, GENETIC; PTEROYLPOLYGLUTAMIC ACIDS; REGRESSION ANALYSIS; STATISTICS, NONPARAMETRIC; TRANSCOBALAMINS; VITAMIN B 12;

EID: 11144354439     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200404090-00025     Document Type: Article

References (21)

1. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM et al. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 55, 1449-1455 (1998).
2. Mattson PM and Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 26, 137-146 (2003).
3. McCaddon A, Davies G, Hudson P, Tandy S and Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 13, 235-239 (1998).
4. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346, 476-483 (2002).
5. Ueland PM, Hustad S, Schneede J et al. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 22, 195-201 (2001).
6. Nishiyama M, Kato Y, Hashimoto M, Yukawa S and Omori K. Apolipoprotein E, methylenetetrahydrofolate reductase (MTHFR) mutation and the risk of senile dementia - an epidemiological study using the polymerase chain reaction (PCR) method. J Epidemiol 10, 163-172 (2000).
7. Pollak RD, Pollak A, Idelson M, Bejarano-Achache I, Doron D and Blumenfeld A. The C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene and vascular dementia. J Am Geriatr Soc 48, 664-668 (2000).
8. Namour F, Olivier J, Abdelmouttaleb I, Adjalla C, Debard R, Salvat C et al. Transcobalamin codon 259 polymorphism in HT-29 and Caco-2 cells and in Caucasians: relation to transcobalamin and homocysteine concentration in blood. Blood 97, 1092-1098 (2001).
9. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of neuropathological assessment of Alzheimer's disease. Neurology 41, 479-486 (1991).
10. Reisberg B, Ferris SH, De Leon MJ and Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 139, 1136-1139 (1982).
11. Anello G, Guéant JL, Romano C, Barone C, Pettinato R, Pillot T et al. Allele ε4 of apolipoprotein gene is less frequent in Down syndrome patient of the Sicilian population and has no influence on the grade of mental retardation. Neurosci Lett 306, 129-131 (2001).
12. Anwar W, Guéant JL, Abdelmouttaleb I, Adjalla C, Gerard P, Lemoel GL et al. Hyperhomocysteinemia is related to residual glomerular filtration and folate, but not to methylenetetrahydrofolate-reductase and methionine synthase polymorphisms, in supplemented end-stage renal disease patients undergoing hemodialysis. Clin Chem Lab Med 39, 747-752 (2001).
13. Bosco P, Guéant-Rodriguez R-M, Anello G, Barone C, Namour F, Caraci F et al. In Sicily, methionine synthase (MTR) 2756 (A → G) polymorphism, double heterozygosity methionine synthase 2756 AG/methionine synthase reductase (MTRR) 66 AG and elevated homocysteinemia are three risk factors for having or being a child with Down syndrome. Am J Med Genet 121, 219-224 (2003).
14. Corder EH, Saunders AM, Stritmatter WJ et al. Gene dose of apolipoprotein E type A allele and the risk of Alzheimer's disease in late-onset families. Science 261, 921-923 (1993).
15. Kruman II, Kumaravel TS, Lohani A et al. Folic acid deficency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in expermental models of Alzheimer's disease. J Neurosci 22, 1752-1762 (2002).
16. Ho PI, Collins SC, Dhitavat S et al. Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. J Neurochem 78 249-253 (2001).
17. Namour F and Gueant JL. Transcobalamin polymorphism and homocysteine concentration in aging. Blood 98, 3498-3499 (2001).
18. Hansen M and Nexo E. The interaction of human transcobalamin isopeptides in cerebrospinal fluid and plasma with cobalamin and the cellular acceptor. Biochim Biophys Acta A 926, 359-364 (1987).
19. Pezacka EH, Jacobsen DW, Luce K and Green R. Glial cells as a model for the role of cobalamin in the nervous system: impaired synthesis of cobalamin coenzymes in cultured human astrocytes following short-term cobalamin- deprivation. Biochem Biopys Res Commun 184, 832-839 (1992).
20. Drouet B, Fifre A, Pincon-Raymond M et al. ApoE protects cortical neurones against neurotoxicity induced by the non-fibrillar C-terminal domain of the amyloid-β peptide. J Neurochem 76, 117-127 (2001).
21. Pak KJ, Chan SL and Mattson MP. Homocysteine and folate deficiency sensitize oligodendrocytes to the cell death-promoting effects of a presenilin-1 mutation and amyloid beta-peptide. Neuromol Med 3, 119-128 (2003).